# Amphastar Pharmaceuticals share price today (Amphastar Pharmaceuticals, Inc., AMPH)

> Amphastar Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AMPH · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/amph

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $27.12 (+6.4% in a year)
- P/E: 16.1× (higher than 56% of the last 4.6 years)
- Revenue (Jun 2026): $184 M (+5.4% on a year ago)
- Profit (Jun 2026): $30.3 M (−2.2% on a year ago)
- Operating margin: 21.6% (−2.6 points on a year ago)
- ROE: 12%, FY25
- ROIC: 9.1%, against a 6.8% cost of capital: +2.3 points

The main question: the share price moved +6.4% in a year while yearly earnings per share moved −33.7%. The difference came from the market paying a higher multiple. ## What is the Amphastar Pharmaceuticals share price today? Amphastar Pharmaceuticals, Inc.'s share price was $27.12 at the close on 3 November 2026. It has been stalling near its high for 10 weeks. That is 21.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $17 and $29, and at that close it sat 83% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 10 years the share price moved +61% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Amphastar Pharmaceuticals pay? Amphastar Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Amphastar Pharmaceuticals on? Amphastar Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Amphastar Pharmaceuticals profitable? Amphastar Pharmaceuticals, Inc. earned $30.3 M of net profit in the Jun 2026 quarter, −2.2% on the same quarter a year earlier. Full-year FY25 profit was $98.1 M. Over 4 years profit has grown 12.1% a year on average. That is 16.5% of the quarter's revenue. The same quarter a year earlier earned $31.0 M. For the full year, FY25 profit was $98.1 M (−38.5% on the year before). Why profit moved: revenue changed +5.4% on a year earlier and the margin moved −2.6 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −42.4% and revenue +1.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Amphastar Pharmaceuticals make, and is it growing? Amphastar Pharmaceuticals, Inc. reported $184 M of revenue in the Jun 2026 quarter, +5.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 13.2% a year on average. The last full year, FY25, came in at $720 M. The last four reported quarters add to $730 M. FY25 revenue was $720 M, −1.7% on the year before. Recent pace: the last four quarters grew +1.1% on average, against 13.2% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.0%, against +1.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −41.7%, against −31.3% a year (rolling over). ## How much of every $100 of sales does Amphastar Pharmaceuticals keep? Amphastar Pharmaceuticals, Inc.'s operating margin was 21.6% in the Jun 2026 quarter, 2.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between 16.4% and 30.6%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.6 percentage points on the year while gross margin changed +1.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Amphastar Pharmaceuticals' profit turning into cash? Over the last 3 years, 140% of Amphastar Pharmaceuticals, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $156 M of operating cash against $98.1 M of profit. After $34.9 M of spending on assets, $121 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Amphastar Pharmaceuticals' cash go? Amphastar Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $114 M on assets over the last 3 years. Averaged over those years that is 5.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $114 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Amphastar Pharmaceuticals' P/E ratio, and how does it compare with its own history? Amphastar Pharmaceuticals, Inc.'s P/E is 16.1×, in the middle of its own history: higher than 56% of past readings. Its usual P/E (the middle reading) is 15.3×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −33.7% while the price moved +6.4%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −16.5% a year; about −12.9% a year came from earnings growth and about −3.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Amphastar Pharmaceuticals business getting better or worse? Amphastar Pharmaceuticals, Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −41.7% in the latest quarter, against +75.2% at its best in 12 quarters, with ROCE falling at 9.4%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Amphastar Pharmaceuticals earn on its capital? Amphastar Pharmaceuticals, Inc. earned a ROE of 12% in FY25. Its return on capital used (ROIC) is 2.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.6% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 13.6% net margin × 0.44× asset turnover × 2.07× leverage (assets divided by equity) ≈ 12.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.1% − 6.8% = +2.3 percentage points. The 6.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 9.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 11.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Amphastar Pharmaceuticals have too much debt? Amphastar Pharmaceuticals, Inc. has total debt of $688 M against shareholder equity of $768 M as of Jun 2026, so its debt is 0.90× its equity. Year by year, that ratio went from 0.23 in FY21 to 0.83 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Amphastar Pharmaceuticals shareholding pattern? 13.8% of Amphastar Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Amphastar Pharmaceuticals from balance-sheet trouble? For Amphastar Pharmaceuticals, Inc., the Z-score is 2.18. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.18 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Amphastar Pharmaceuticals rank in its industry? There is no score against its industry: Amphastar Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Amphastar Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Amphastar Pharmaceuticals in size? Amphastar Pharmaceuticals is the 32nd largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Eton Pharmaceuticals, Inc., Pacira BioSciences, Inc. and Cronos Group Inc. Just below it: Harrow, Inc., Esperion Therapeutics, Inc. and Collegium Pharmaceutical, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) $1.5 billion
2. [Pacira BioSciences, Inc.](https://www.sectoralpha.in/us/stocks/pcrx) $1.5 billion
3. [Cronos Group Inc.](https://www.sectoralpha.in/us/stocks/cron) $1.3 billion
4. Amphastar Pharmaceuticals, Inc. $1.2 billion
5. [Harrow, Inc.](https://www.sectoralpha.in/us/stocks/hrow) $1.1 billion
6. [Esperion Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/espr) $819 million
7. [Collegium Pharmaceutical, Inc.](https://www.sectoralpha.in/us/stocks/coll) $773 million

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Carter's, Inc.](https://www.sectoralpha.in/us/stocks/cri) $1.2 billion · Apparel Retail
2. [Ibotta, Inc.](https://www.sectoralpha.in/us/stocks/ibta) $1.2 billion · Software - Application
3. Amphastar Pharmaceuticals, Inc. $1.1 billion
4. [Artivion, Inc.](https://www.sectoralpha.in/us/stocks/aort) $1.1 billion · Medical Devices
5. [Napco Security Technologies, Inc.](https://www.sectoralpha.in/us/stocks/nssc) $1.1 billion · Security & Protection Services

## What else do people ask about Amphastar Pharmaceuticals? ### What were Amphastar Pharmaceuticals's latest quarterly results? Amphastar Pharmaceuticals, Inc. reported revenue of $184 M and net profit of $30.3 M for the Jun 2026 quarter. Revenue rose 5.4% and profit fell 2.2% compared with a year earlier. Earnings per share were $0.67. The operating margin was 21.6%, 2.6 percentage points lower than a year earlier (as of 3 November 2026). ### What is Amphastar Pharmaceuticals's market cap? Amphastar Pharmaceuticals, Inc.'s market capitalisation is $1.2 B at a stock price of $27.12. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Amphastar Pharmaceuticals performing? Amphastar Pharmaceuticals, Inc.'s share price has been stalling near its high for 10 weeks. In its latest quarter, revenue rose 5.4% and profit fell 2.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running (as of 3 November 2026). ### Will Amphastar Pharmaceuticals's stock price go up? This page does not forecast Amphastar Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $27.12, and it has been stalling near its high for 10 weeks. Its P/E of 16.1× is higher than 56% of its own last 5 years (as of 3 November 2026). ### Where is Amphastar Pharmaceuticals in its business cycle? Amphastar Pharmaceuticals, Inc.'s FY25 operating margin was 22.7%, against a 5-year range of 16.4% to 30.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 21.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Amphastar Pharmaceuticals story? The main question: the share price moved +6.4% in a year while yearly earnings per share moved −33.7%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Amphastar Pharmaceuticals a stock worth studying right now? What the numbers show: Amphastar Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.